Recon: J&J boosts cancer portfolio with $3.05B Halda acquisition; RFK Jr. reportedly discussed scaling back Makary’s role at FDA
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States